PTCH1 and nevoid basal cell carcinoma syndrome: Aberrant hyper-activation of this pathway was first identified in Gorlin’s syndrome [6, 7], where an autosomal dominant mutation in the tumor suppressor gene PTCH1 predisposed patients to basal cell carcinoma (BCC) and/or central nervous system (CNS) malignancy medulloblastoma (MB) [8].